Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Standard Biotools (LAB) EBITDA (2016 - 2026)

Standard Biotools has reported EBITDA over the past 16 years, most recently at -$24.6 million for Q4 2025.

  • Quarterly EBITDA fell 129.9% to -$24.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$116.2 million through Dec 2025, down 234.8% year-over-year, with the annual reading at -$110.2 million for FY2025, 480.78% down from the prior year.
  • EBITDA was -$24.6 million for Q4 2025 at Standard Biotools, up from -$32.9 million in the prior quarter.
  • Over five years, EBITDA peaked at $82.4 million in Q4 2024 and troughed at -$60.2 million in Q1 2024.
  • The 5-year median for EBITDA is -$24.6 million (2025), against an average of -$21.1 million.
  • The largest YoY upside for EBITDA was 485.39% in 2024 against a maximum downside of 262.7% in 2024.
  • A 5-year view of EBITDA shows it stood at -$19.6 million in 2021, then fell by 7.65% to -$21.1 million in 2022, then decreased by 1.3% to -$21.4 million in 2023, then surged by 485.39% to $82.4 million in 2024, then tumbled by 129.9% to -$24.6 million in 2025.
  • Per Business Quant, the three most recent readings for LAB's EBITDA are -$24.6 million (Q4 2025), -$32.9 million (Q3 2025), and -$25.7 million (Q2 2025).